NEW YORK (GenomeWeb) – Horizon Discovery announced today that it has entered an agreement with Roche Diagnostics to develop immunohistochemistry reference standards for oncology assays.

The company will develop and provide reference standard material for neurotrophic tropomyosin receptor kinase (NTRK) fusion biomarkers. Effective use of compounds against fusion proteins resulting from NTRK gene rearrangements depends on accurate genotyping of patients, Horizon noted in a statement, and this is typically done using immunohistochemistry.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.